Patents by Inventor Paul A. DaSilva Jardine

Paul A. DaSilva Jardine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-APOC3 ANTIBODIES
    Publication number: 20220251180
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: December 30, 2021
    Publication date: August 11, 2022
    Inventors: Paul DASILVA-JARDINE, Hans De Haard
  • ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220220193
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: December 23, 2021
    Publication date: July 14, 2022
    Inventors: Paul DASILVA-JARDINE, Hans DE HAARD
  • Polynucleotides encoding anti-ApoC3 antibodies
    Patent number: 11248042
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 15, 2022
    Assignee: STATEN BIOTECHNOLOGY B.V.
    Inventors: Paul DaSilva-Jardine, Hans de Haard
  • Anti-ApoC3 antibodies
    Patent number: 11248041
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 15, 2022
    Assignee: STATEN BIOTECHNOLOGY B.V.
    Inventors: Paul DaSilva-Jardine, Hans de Haard
  • Anti-ApoC3 antibodies and methods of use thereof
    Patent number: 11242381
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: February 8, 2022
    Assignee: STATEN BIOTECHNOLOGY B.V.
    Inventors: Paul Dasilva-Jardine, Hans De Haard
  • ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220025026
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: July 7, 2021
    Publication date: January 27, 2022
    Inventors: Paul DASILVA-JARDINE, Hans DE HAARD, James A. LANDRO
  • ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220025027
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: July 7, 2021
    Publication date: January 27, 2022
    Inventors: Paul DASILVA-JARDINE, Hans DE HAARD, James A. LANDRO
  • ANTIBODIES SPECIFIC FOR HUMAN AND CYNOMOLGUS APOC3 AND METHODS OF USE THEREOF
    Publication number: 20210347865
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human or cynomolgus ApoC3) and antagonizes ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: April 2, 2021
    Publication date: November 11, 2021
    Inventors: Paul DASILVA-JARDINE, Hans DE HAARD
  • Anti-ApoC3 antibodies and methods of use thereof
    Patent number: 11091539
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: August 17, 2021
    Assignee: STATEN BIOTECHNOLOGY B.V.
    Inventors: Paul DaSilva-Jardine, Hans de Haard, James A. Landro
  • ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200239555
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: December 13, 2019
    Publication date: July 30, 2020
    Inventors: Paul DaSilva-Jardine, Hans de Haard
  • ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200216523
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: December 13, 2019
    Publication date: July 9, 2020
    Inventors: Paul DaSilva-Jardine, Hans de Haard
  • ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200148755
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: October 21, 2019
    Publication date: May 14, 2020
    Inventors: Paul DASILVA-JARDINE, Hans DE HAARD
  • Anti-APOC3 antibodies and compositions thereof
    Patent number: 10538583
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: January 21, 2020
    Assignee: STATEN BIOTECHNOLOGY B.V.
    Inventors: Paul DaSilva-Jardine, Hans de Haard
  • ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190241648
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: January 7, 2019
    Publication date: August 8, 2019
    Inventors: Paul DaSilva-Jardine, Hans de Haard, James A. Landro
  • ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190135906
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: January 15, 2019
    Publication date: May 9, 2019
    Inventors: Paul DaSilva-Jardine, Hans de Haard
  • Estrogen Agonists/Antagonists For Preventing Breast Cancer
    Publication number: 20100317712
    Abstract: Compounds of this formula are useful for preventing breast cancer.
    Type: Application
    Filed: August 20, 2010
    Publication date: December 16, 2010
    Inventors: Kimberly O. Cameron, Paul A. Dasilva-Jardine, Hua Zhu Ke, Robert L. Rosati
  • 5-HT receptor ligands and uses thereof
    Patent number: 6894050
    Abstract: Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: May 17, 2005
    Assignee: Pfizer Inc.
    Inventors: Phoebe Chiang, William A. Novomisle, Willard M. Welch, Jr., Angel Guzman-Perez, Paul A. DaSilva-Jardine, Ravi S. Garigipati, Kevin K. Liu
  • 5-HT receptor ligands and uses thereof
    Publication number: 20050090503
    Abstract: Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein.
    Type: Application
    Filed: August 19, 2004
    Publication date: April 28, 2005
    Inventors: Phoebe Chiang, William Novomisle, Willard Welch, Angel Guzman-Perez, Paul DaSilva-Jardine, Ravi Garigipati, Kevin Liu
  • 5-HT receptor ligands and uses thereof
    Publication number: 20050020604
    Abstract: Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein.
    Type: Application
    Filed: August 19, 2004
    Publication date: January 27, 2005
    Inventors: Phoebe Chiang, William Novomisle, Willard Welch, Angel Guzman-Perez, Paul DaSilva-Jardine, Ravi Garigipati, Kevin Liu
  • 5-Substituted-6-cyclic-5,6,7,8-tetrahydronaphthalen 2-ol compounds which are useful for treating osteoporosis
    Patent number: RE39558
    Abstract: Compounds of this formula are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: April 10, 2007
    Assignee: Pfizer Inc.
    Inventors: Kimberly O. Cameron, Paul A. DaSilva Jardine, Robert L. Rosati